Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy.
Intercellular adhesion molecule-1 (ICAM-1, CD54), a molecule bound to the cell surface membrane, mediates various cell-cell interactions in inflammation and immunosurveillance. By means of a new specific enzyme-linked immunosorbent assay (ELISA) for soluble ICAM-1, free circulating ICAM-1 was measured in serum from five healthy volunteers, 10 melanoma patients at different stages of their disease, and eight patients receiving high-dose interleukin-2 (IL-2) for metastatic melanoma. No correlation between the concentration of circulating ICAM-1 and the tumor burden could be detected. In melanoma patients receiving high-dose IL-2, we observed an increase of circulating ICAM-1 of up to 200%, compared to the concentration prior to therapy, ranging between 4 and 13 ng/ml. The increase in circulating ICAM-1 was associated with the induction of tumor necrosis factor-alpha and interferon-gamma.
Department of Dermatology, University of Würzburg, F.R.G.
J C
JC
Becker
R
R
Dummer
A
A
Schwinn
A A
AA
Hartmann
G
G
Burg
D015815:Cell Adhesion Molecules / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007167:Immunotherapy; D018799:Intercellular Adhesion Molecule-1; D007376:Interleukin-2 / Q000627:therapeutic use*; D008545:Melanoma / Q000097:blood / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging
D015815:Cell Adhesion Molecules; D007376:Interleukin-2; D018799:Intercellular Adhesion Molecule-1